Vivani Medical
VANIVivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants designed to improve medication adherence and tolerability for chronic diseases.
Earnings
Next report
Aug 12, 2026 (In 3 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants designed to improve medication adherence and tolerability for chronic diseases. The company's proprietary NanoPortal technology enables the near constant-rate delivery of medicines, such as GLP-1 receptor agonists, for six months or longer via a reversible titanium-oxide membrane system. Their primary focus is addressing metabolic conditions including obesity and type 2 diabetes through a portfolio of implantable candidates.
Vivani holds a unique position as a developer of the only known reversible GLP-1 implants in clinical or preclinical development, targeting the high-growth obesity and diabetes markets.
Questions, answered.
- What is Vivani Medical's market cap?
- Vivani Medical (VANI) has a market capitalization of $120.7M and trades on NASDAQ.
- Who are Vivani Medical's competitors?
- Vivani Medical's key competitors include Viking Therapeutics, Eli Lilly and Company, Amgen, and others. These companies compete in similar markets and product categories.
- Who does Vivani Medical partner with?
- Vivani Medical's notable partners include Okava Pharmaceuticals, Inc., Novo Nordisk.
- What subsidiaries does Vivani Medical have?
- Vivani Medical's subsidiaries include Cortigent, Inc., Nano Precision Medical, Inc..
- Where is Vivani Medical headquartered?
- Vivani Medical is headquartered in United States of America and employs approximately 37 people. It has been publicly traded since 2022.